TMEM33 deletion potentiates anti-tumor CD8⁺ T cell immunity

Area of Science:

• Immunology
• Cancer Biology
• Molecular Biology

Background:

• Cancer immunotherapies aim to enhance T cell-mediated anti-tumor immunity.
• TMEM33, an endoplasmic reticulum transmembrane protein, has known roles in viral immunity and homeostasis but its function in tumor immunosurveillance is unexplored.

Purpose of the Study:

• To investigate the role of TMEM33 in anti-tumor CD8+ T cell responses and its impact on melanoma progression and patient survival.

Main Methods:

• Utilized murine genetic models (Tmem33-/- mice) to study T cell responses in vivo.
• Performed ex vivo analysis of T cell activation and function.
• Adoptively transferred T cells in tumor models.
• Correlated TMEM33 expression with survival in a metastatic melanoma patient cohort.

Main Results:

• Tmem33-/- mice showed delayed melanoma growth and increased CD8+ T cell infiltration.
• TMEM33 deletion in T cells enhanced progenitor exhausted cell (Tpex) maintenance, improved effector function, and promoted effector memory expansion.
• Lower TMEM33 expression in patient CD8+ T cells correlated with improved survival and higher TCF-7 (TCF-1) levels.

Conclusions:

• TMEM33 intrinsically limits anti-tumor CD8+ T cell responses by regulating Tpex cell fate.
• Modulating TMEM33 may enhance the efficacy of cancer immunotherapies and cell-based therapies.
• TMEM33 serves as a potential prognostic biomarker in metastatic melanoma.